Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Double-blind, Randomized, Parallel Group, Placebo Controlled, Multicentre, Phase II Study to Investigate the Efficacy, GPCR Autoantibody Neutralizing Effect, Safety, and Tolerability of BC 007 in Participants With Long COVID

NCT05911009 is registered in ClinicalTrials.gov with Berlin Cures GmbH as lead sponsor.

NCT NCT05911009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05911009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Double-blind, Randomized, Parallel Group, Placebo Controlled, Multicentre, Phase II Study to Investigate the Efficacy, GPCR Autoantibody Neutralizing Effect, Safety, and Tolerability of BC 007 in Participants With Long COVID
Lead sponsor
Berlin Cures GmbH
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2023
Completion date
September 4, 2024
Enrollment
119 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

long covid